Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
VYGR | US
1.22
20.96%
Healthcare
Biotechnology
30/06/2024
04/10/2024
7.04
6.05
7.07
6.05
Voyager Therapeutics Inc. a biotechnology company focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01 an anti-tau antibody program for the treatment of Alzheimer's disease. It also develops VY-FXN01 to treat Friedreich's ataxia; superoxide dismutase 1 gene silencing program for the treatment of amyotrophic lateral sclerosis; and GBA1 gene replacement program to treat Parkinson's disease. In addition the company develops research program for the treatment of Huntington's disease. It has collaboration and license agreements with Neurocrine Biosciences Inc.; Pfizer Inc.; and Novartis Pharma A.G. for the research development and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics Inc. was incorporated in 2013 and is headquartered in Cambridge Massachusetts.
View LessStrength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
High Short-term Volatility
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
113.0%1 month
76.3%3 months
67.0%6 months
54.4%21.67
-
0.95
0.14
0.11
2.59
0.14
-
-1.78M
383.91M
383.91M
-
-50.80
-
509.50
3.38
11.04
9.29
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.36
Range1M
1.36
Range3M
3.84
Rel. volume
2.65
Price X volume
9.28M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Taysha Gene Therapies Inc | TSHA | Biotechnology | 2.01 | 417.91M | -1.95% | n/a | 53.02% |
LRMR | LRMR | Biotechnology | 6.65 | 408.81M | 5.72% | n/a | 2.65% |
Sage Therapeutics Inc | SAGE | Biotechnology | 6.64 | 405.37M | -4.87% | n/a | 0.22% |
Theravance Biopharma Inc | TBPH | Biotechnology | 8.1 | 396.27M | -1.34% | n/a | 24.09% |
Biomea Fusion Inc. Common Stock | BMEA | Biotechnology | 10.48 | 379.48M | 3.46% | n/a | 9.95% |
ZVRA | ZVRA | Biotechnology | 7.2 | 378.85M | 1.12% | n/a | 183.10% |
C4 Therapeutics Inc | CCCC | Biotechnology | 5.38 | 373.04M | -0.92% | n/a | 27.69% |
Anika Therapeutics Inc | ANIK | Biotechnology | 24.99 | 369.77M | -0.12% | n/a | 13.35% |
Fate Therapeutics Inc | FATE | Biotechnology | 3.22 | 366.69M | 0.31% | n/a | 25.33% |
ITOS | ITOS | Biotechnology | 10.02 | 365.95M | 2.04% | n/a | 0.83% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.02 | 57.65M | -4.67% | n/a | 268.43% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 2.59 | 0.76 | Expensive |
Ent. to Revenue | 0.14 | 3,674.48 | Cheaper |
PE Ratio | 21.67 | 38.01 | Cheaper |
Price to Book | 0.95 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 66.99 | 74.67 | Par |
Debt to Equity | 0.14 | -1.82 | Expensive |
Debt to Assets | 0.11 | 0.26 | Cheaper |
Market Cap | 383.91M | 3.73B | Emerging |